Induction of bradykinin B1 receptors in vivo in a model of ultra‐violet irradiation‐induced thermal hyperalgesia in the rat
Open Access
- 1 December 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 110 (4) , 1441-1444
- https://doi.org/10.1111/j.1476-5381.1993.tb13982.x
Abstract
1 The role of bradykinin B1 receptors in the thermal hyperalgesia following unilateral ultra-violet (u.v.) irradiation of the hindpaw of rats has been investigated. 2 In non-irradiated (naive) animals the B1 receptor agonist des-Arg9-bradykinin and bradykinin (BK) (up to 1 μmol kg−1 i.v.) had no effect on withdrawal latency to a noxious heat stimulus when administered 60 min before testing. 3 Following exposure of one hindpaw to strong u.v. irradiation the withdrawal latency of the u.v.-treated paw to radiant noxious heat fell by a maximum of 50% after 48 h. There was no reduction in latency in the contralateral paw. 4 des-Arg9-BK (1–100 nmol kg−1 i.v.) administered 24 h after u.v. exposure caused a further dose-dependent fall (50 ± 4% reduction from saline injected animals at 100 nmol kg−1 i.v.) in withdrawal latency in the u.v.-treated paw when measured 60 min after injection. The withdrawal latency of the contralateral paw was also reduced but to a lesser extent following des-Arg9-BK (100 nmol kg−1 i.v.) with a maximum reduction of 19 ± 3%. 5 Bradykinin also induced a further reduction in withdrawal latency (33 ± 5% reduction at 1 μmol kg−1) although it was not as effective as des-Arg9-BK. Bradykinin did not reduce the withdrawal latency in the contralateral paw. 6 The hyperalgesic action of both des-Arg9-BK (10 nmol kg−1 i.v.) and bradykinin (100 nmol kg−1 i.v.) were antagonized by the B1 receptor antagonist, des-Arg9,Leu8-BK (200 nmol kg−1 i.v.) but not by the B2 receptor antagonist, HOE 140 (0.5 μmol kg−1 i.v.). 7 The results suggest that in conditions of inflammatory hyperalgesia bradykinin B1 receptors are induced both locally and distant to the inflamed area, activation of which leads to further thermal hyperalgesia. In addition, in these conditions bradykinin appears to act predominantly via B1 receptors, presumably after degradation to des-Arg9-BK.Keywords
This publication has 28 references indexed in Scilit:
- Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg9, [Leu8]-BK and HOE 140, in two models of persistent hyperalgesia in the ratPain, 1993
- Induction of vascular smooth muscle bradykinin B1 receptorsin vivo during antigen arthritisInflammation Research, 1991
- The effects of bradykinin agonists and antagonists on visceral polymodal receptor activitiesPain, 1990
- The kallikrein-kininogen-kinin system in chronic inflammationInflammation Research, 1989
- Pharmacological modulation of the up-regulated responses to des-Arg9-bradykinin in vivo and in vitroImmunopharmacology, 1989
- Bradykinin stimulates tumor necrosis factor and interleukin‐1 release from macrophagesFEBS Letters, 1989
- Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in cultureInflammation Research, 1988
- Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivoBritish Journal of Pharmacology, 1987
- Heterogeneity in mechanisms of bradykinin action in canine isolated blood vesselsEuropean Journal of Pharmacology, 1987
- Excitatory effects of 5-hydroxytryptamine, histamine and potassium ions on muscular group IV afferent units: A comparison with bradykininBrain Research, 1976